Skip to main content

Table 3 Cardiac Parameters and Baseline and Endpoint

From: Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

  Placebo N = 116 IR-MPH (tid) N = 102 OROS-MPH N = 67  
  mean ± sd mean ± sd mean ± sd Omnibus Statistic
Systolic Blood Pressure     
   Baseline 121.4 ± 13.7 125.6 ± 13.3 119.2 ± 13.2  
   Endpoint 120.3 ± 13.0 127.5 ± 12.7 122.6 ± 11.9  
   Change -1.2 ± 12.3 2.0 ± 12.6 3.5 ± 11.8 χ2 (2) = 6.7, p = 0.03
Diastolic Blood Pressure     
   Baseline 71.3 ± 10.5 75.1 ± 9.6 68.6 ± 8.9  
   Endpoint 69.8 ± 10.0 77.3 ± 9.2 72.8 ± 9.3  
   Change -1.5 ± 8.4 2.1 ± 8.8 * 4.0 ± 8.5 * χ2 (2) = 19.9, p < 0.0001
Pulse     
   Baseline 76.2 ± 10.9 76.5 ± 12.5 78.2 ± 11.6  
   Endpoint 71.5 ± 10.9 82.3 ± 12.7 82.9 ± 12.6  
   Change -4.8 ± 11.7 5.9 ± 12.9* 4.5 ± 10.5*,$ χ2 (2) = 27.9, p < 0.0001
PR Interval     
   Baseline 153.2 ± 18.7 151.3 ± 25.8 151.3 ± 18.3  
   Endpoint 151.8 ± 17.8 147.9 ± 20.4 147.9 ± 21.1  
   Change -1.1 ± 13.7 -2.5 ± 11.8 -1.2 ± 11.3 χ2 (2) = 0.6, p = 0.8
QRS Interval     
   Baseline 87.5 ± 10.9 90.1 ± 12.8 93.3 ± 9.9  
   Endpoint 88.1 ± 10.4 87.8 ± 10.9 91.5 ± 11.3  
   Change 0.5 ± 8.6 -1.2 ± 9.7 -1.2 ± 5.8 χ2 (2) = 3.1, p = 0.2
QTc Interval@     
   Baseline 413.4 ± 18.0 417.1 ± 19.8 412.5 ± 15.6  
   Endpoint 413.6 ± 16.3 420.9 ± 18.4 414.5 ± 18.8  
   Change 0.5 ± 18.4 6.1 ± 16.0 1.9 ± 15.7 χ2 (2) = 2.7, p = 0.3
  1. *, p < 0.05 versus Placebo, $, p < 0.05 versus IR-MPH (tid), @, Bazzett's Correction